Moleculin Biotech (FRA:MOL0) 9-Day RSI: N/A (As of Jul. 05, 2026)


FRA:MOL0 Moleculin Biotech Inc FRA:MOL0
30 GF Score
Price €161.25
! 1 Warning Sign
View Full Analysis

What is Moleculin Biotech 9-Day RSI?

The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.

As of today (2026-07-05), Moleculin Biotech's 9-Day RSI is N/A.

The industry rank for Moleculin Biotech's 9-Day RSI or its related term are showing as below:

FRA:MOL0's 9-Day RSI is not ranked *
in the Biotechnology industry.
Industry Median: 53.73
* Ranked among companies with meaningful 9-Day RSI only.

Moleculin Biotech  (FRA:MOL0) 9-Day RSI Explanation

The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.

Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.

RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.


Moleculin Biotech 9-Day RSI Related Terms


FRA:MOL0 vs JAGX, BCDA, AKTX: 9-Day RSI Comparison

For the Biotechnology subindustry, Moleculin Biotech's 9-Day RSI, along with its competitors' market caps and 9-Day RSI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Moleculin Biotech 9-Day RSI vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Moleculin Biotech's 9-Day RSI distribution charts can be found below:

* The bar in red indicates where Moleculin Biotech's 9-Day RSI falls into.


FRA:MOL0
30GF Score
Moleculin Biotech Inc FRA:MOL0
9-Day RSI is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Moleculin Biotech  (FRA:MOL0) 9-Day RSI Calculation

The formula for calculating RSI is:

RSI=100[ 100 / ( 1 + Average Gain / Average Loss )]

* Note that the formula uses a positive value for the average loss.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Moleculin Biotech Business Description

Other Exchanges MBRX:USA0K2H:UK
Address 5300 Memorial Drive, Suite 950, Houston, TX, USA, 77007
Moleculin Biotech Inc is a late-stage pharmaceutical development company currently evaluating Annamycin, also known as L-Annamycin and by its generic name naxtarubicin. The company has two additional portfolios of technologies for hard-to-treat cancers and viruses with clinical and preclinical research funded by investigators at academic institutions. The Company operates in one reportable segment, which is the development and commercialization of drug products.
30GF Score

Get the complete analysis for FRA:MOL0

9-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€161.25
Price